Lambe, T.,Carey, J. B.,Li, Y.,Spencer, A. J.,van Laarhoven, A.,Mullarkey, C. E.,Vrdoljak, A.,Moore, A. C.,Gilbert, S. C.

2013

Sci Rep

Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1

Validated

WOS: 50 ()

Adenoviridae/genetics/*immunology Administration, Intranasal Animals CD8-Positive T-Lymphocytes/cytology/immunology/metabolism Cytokines/metabolism Female Genetic Vectors/genetics/metabolism Immunization, Secondary Influenza Vaccines/biosynthesis/genetics/immunology Influenzavirus A/*immunology/metabolism Injections, Intradermal Interferon-gamma/metabolism Mice Mice, Inbred BALB C Mice, Inbred C57BL Orthomyxoviridae Infections/immunology/prevention & control RNA-Binding Proteins/genetics/metabolism Spleen/cytology/metabolism Vaccinia virus/genetics/*immunology Viral Core Proteins/genetics/metabolism Viral Matrix Proteins/genetics/metabolism

3

1443

Alternate prime/boost vaccination regimens employing recombinant replication-deficient adenovirus or MVA, expressing Influenza A virus nucleoprotein and matrix protein 1, induced antigen-specific T cell responses in intradermally (ID) vaccinated mice; with the strongest responses resulting from Ad/MVA immunization. In BALB/C mice the immunodominant response was shifted from the previously identified immunodominant epitope to a novel epitope when the antigen was derived from A/Panama/2007/1999 rather than A/PR/8. Alternate immunization routes did not affect the magnitude of antigen-specific systemic IFN-gamma response, but higher CD8(+) T-cell IFN-gamma immune responses were seen in the bronchoalveolar lavage following intransal (IN) boosting after intramuscular (IM) priming, whilst higher splenic antigen-specific CD8(+) T cell IFN-gamma was seen following IM boosting. Partial protection against heterologous influenza virus challenge was achieved following either IM/IM or IM/IN but not ID/ID immunization. These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naive infants.

2045-2322 (Electronic) 20

http://www.ncbi.nlm.nih.gov/pubmed/23485942

10.1038/srep01443